<DOC>
	<DOCNO>NCT01547091</DOCNO>
	<brief_summary>Rheumatoid arthritis chronic systemic disease , characterize chronic inflammation synovial tissue . Rheumatoid arthritis eventually result destruction cartilage , bone ligament joint deformity . The underlying hypothesis umbilical cord-derived mesenchymal stem cell ( UC-MSCs ) anti-inflammatory effect thus potentially alleviate progression rheumatoid arthritis . The study explore safety efficacy UC-MSCs transplantation treatment rheumatoid arthritis .</brief_summary>
	<brief_title>Safety Efficacy Study Umbilical Cord-Derived Mesenchymal Stem Cells Rheumatoid Arthritis</brief_title>
	<detailed_description>This study support National Natural Science Foundation China ( 30872618 ) ï¼ŒThe Shanxi Province Social Development Public Relations Project ( 2012K13-02-35 ) , The Military Medicine Public Health Plan ( CLZ120GA23 )</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>All patient fulfil classification criterion ( 2010 ) rheumatoid arthritis , man woman age 18 70 year old . Patients must inform investigational nature study give write informed consent accordance institutional hospital guideline . Women reproductive potential may participate unless agree use effective contraceptive method trial . Women childbearing potential must pregnancy test perform within 72 hour prior initiation treatment . Any history ongoing , significant recur infection . Any active inflammatory disease RA . Significant cardiac pulmonary disease . Endstage renal failure . Pregnant nursing woman may participate due possibility fetal harm harm nursing infant treatment regimen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Mesenchymal Stem Cells</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>